The therapeutic landscape for psoriasiform dermatitis is evolving, with emerging data on the efficacy of targeted agents such as JAK inhibitors, PDE4 inhibitors, and biologics directed against IL-17 and IL-23. Here, PDE4A is linked to Psoriasiform dermatitis.